SCHEMBL312399

SCHEMBL312399

O=c1cc(-c2ccc(O)c(O)c2)oc2ncccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.62
ALOX5 P09917 5/20 0.62
POLH Q9Y253 5/20 0.62
MAPT P10636 5/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
TNKS O95271 4/20 0.62
CYP3A4 P08684 4/20 0.62
ALOX15 P16050 4/20 0.62
HSD17B10 Q99714 4/20 0.62
HPGD P15428 4/20 0.62
PARP1 P09874 3/20 0.62
TNKS2 Q9H2K2 3/20 0.62
IP6K2 Q9UHH9 3/20 0.62
MAPK1 P28482 3/20 0.62
FTO Q9C0B1 3/20 0.62
ALDH1A1 P00352 2/20 0.62
ST6GAL1 P15907 1/20 0.62
DHODH Q02127 1/20 0.62
MCL1 Q07820 1/20 0.55
TERT O14746 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311467 0.88 KDM4E (0.48) KDM4EALOX5POLHMAPTSMN1; SMN2
SCHEMBL311979 0.88 CYP1B1 (0.48) KDM4EALOX5POLHMAPTSMN1; SMN2
SCHEMBL312246 0.88 KDM4E (0.48) KDM4EALOX5POLHMAPTSMN1; SMN2
SCHEMBL311824 0.88 CSNK2A2 (0.53) KDM4EALOX5POLHMAPTSMN1; SMN2
SCHEMBL312123 0.87 KDM4E (0.47) KDM4EALOX5POLHMAPTSMN1; SMN2
SCHEMBL311324 0.86 NPC1 (0.60) KDM4EMAPTSMN1; SMN2TNKSCYP3A4
SCHEMBL311321 0.85 CSNK2A2 (0.67) KDM4EALOX5MAPTSMN1; SMN2CYP3A4
SCHEMBL1644978 0.81 KDM4E (0.42) KDM4EALOX5POLHMAPTSMN1; SMN2
SCHEMBL1644987 0.81 CYP1B1 (0.63) KDM4EMAPTSMN1; SMN2TNKSCYP3A4
SCHEMBL1645872 0.81 CYP1B1 (0.53) KDM4EALOX5POLHMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 KDM4E 3504/4885ALOX5 986/4885POLH 4318/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 KDM4E 3504/4885ALOX5 986/4885POLH 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.